Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).
Lyndsey Runaas, MD
Advertisement
Articles by Lyndsey Runaas, MD
Advertisement
Latest Updated Articles
Dr. Runaas on Impactful Targeted Therapies in FLT3-Positive AMLPublished: May 31st 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Frontline Dato-DXd for Metastatic TNBC Ineligible for Immunotherapy
2
FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC
3
On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care
4
Real-World Analysis Supports Rethinking Upfront Dose Intensity of Enfortumab Vedotin in Advanced Urothelial Cancer
5